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Background: The prognosis of patients with liver metastases from gastric cancer (LMGC) is dismal, and little is
known about prognostic factors in these patients; so justification for surgical resection is still controversial.
Furthermore the results of chemotherapy for these patients are disappointing. The purpose of this study was to
review recent outcomes of hepatectomy for LMGC and to determine the suitable candidates for surgery, assessing
the surgical results and clinicopathologic features. Moreover we compare these results with those obtained with
alternative treatments.
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Gastric cancer is the fourth most common cancer world-
wide and account for 1.5% of all new diagnoses and 5.2%
of all cancer deaths [1,2]. At the time of diagnosis 35%
of patients present with evidence of distant metastases
and 4% to 14% have metastatic disease to the liver [3,4].
Although the effectiveness of liver resection for meta-
static colorectal cancer has been already established [5-
7], reports of hepatic resection for liver metastases of
gastric cancer are rare and its significance is still contro-
versial [8]. In fact a number of studies reported that the
effect and benefit of hepatic resection for either syn-
chronous or metachronous gastric hepatic metastases
(LMGC) on survival was dubious [9]. Furthermore the
surgical indications for liver metastases of colorectal
cancer have been expanded to include all technically re-
sectable metastases numbering 4 or more [10]. On the
contrary, the surgical indications for liver metastases of
gastric cancer must be carefully determined because of
the more severe biologic nature of this disease [11].
Most patients with gastric cancer with concomitant
liver metastases are excluded from candidates for cura-
tive surgery accompanied with hepatic resection due to
incurable simultaneous factor such as peritoneal* Correspondence: Fabrizio.romano@unimib.it
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reproduction in any medium, provided the ordissemination, widespread lymph nodal metastases, and
direct invasion to adjacent structures [12]. In fact LMGC
often represent only a part of a generalized spread of the
primary tumor (‘the tip of the iceberg’). Furthermore
very few patient with LMGC are good candidates for
liver surgery due to multiple, scattered, bilobar lesions
[13]. Patients with isolated metastases are unusual,
accounting for 0.5% of cases in the Linhares’s series [14].
On the other hand metastatic liver involvement, which
occurs in up to 50% of patients with gastric cancer,
makes long-term survival without treatment impossible,
with a median survival of 6 months. These data show
growth to 7 to 15 months with chemotherapy schedules.
There are no adequate large prospective studies detailing
the natural history of metastatic gastric carcinoma and
long-term survival. However, two small randomized
trials compared best supportive care vs. combination
chemotherapy and found that no patients treated with
supportive care lived for >1 year [15,16]. Survival data
for patients with metastatic gastric cancer (MGC) to the
liver only are also limited. In a study analyzing 643
patients enrolled in five separate chemotherapy trials by
the Japanese Clinical Oncology Group (JCOG), 5-year
survival for patients with metastases confined to the
liver and treated with systemic therapy alone was 1.7%
[17]. Palliative chemotherapy using various regimens has
been widely used as the treatment of choice, but only
modest improvements in overall survival have beenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Classification of hepatic metastases from gastric
cancer as proposed by the Japanese Gastric Cancer
Association, 1998
H-O No liver metastases
H-1 Liver metastases limited to one lobe of the liver
H-2 Isolated diverse metastases in both lobes of the liver
H-3 Multiple distributed metastases in both lobes of the liver
Romano et al. World Journal of Surgical Oncology 2012, 10:157 Page 2 of 12
http://www.wjso.com/content/10/1/157observed, with median survival increasing from approxi-
mately 3 months to 7 to 15 months. Long-term survival
is rarely reported [18-20]. In particular, considering the
few trials evaluating systemic chemotherapy in the sub-
set of patients with liver-only metastatic involvement, 5-
year survival rates do not reach 2% [21].
Baba et al. have shown that the outcome for patients
with non-curative resection for advanced gastric cancer is
extremely poor [22], while several authors have reported
on their limited experiences of surgical complete resection
of the metastatic tumors in selected patients of LMGC,
with 5-year survival rates ranging from 0% to 38% [23-25],
considering patients with liver metastases as sole meta-
static site. However, considering survival performances
extrapolated from a cohort of 1,452 patients submitted to
hepatic resection for non-colorectal non-endocrine liver
metastases, Adam et al. [26] observed that metastases
from gastric adenocarcinoma performed in an intermedi-
ate way, ranking 10th in a list of 18 primaries. Moreover a
recent review of the literature about LMGC report a me-
dian 1-, 3-, and 5-year survival on 436 patients of 62%,
30%, and 26.5%, respectively, and a median survival of 17
months [27]. So even if the percentage of patients who
may benefit from resection is probably small, only surgery
is able to obtain long-term survival. Therefore the deter-
mination of selection criteria for hepatic resection and
conditions for long-term survival after hepatectomy for
LMGC are crucial.
We reviewed the literature in which numerous factors
were examined and their relationship to outcome
assessed, in order to determine the benefits and the lim-
its of hepatic resection for gastric metastases and to
identify selection criteria for good outcome. In fact iden-
tification of prognostic factors that predict outcome fol-
lowing surgical resection of gastric hepatic metastases
should assist in identification of patients most likely to
benefit from this intervention, or more importantly, as-
sist in identification of patients unlikely to benefit.
Moreover, we analyze a more recent study which com-
pares the surgical approach to other treatment modal-
ities such chemotherapy or radiofrequency.
Indications
A literature review of papers written in English was per-
formed. The criteria for hepatic resection offered by
Okano et al. [28] are broadly defined: hepatic resection
is indicated in patients: (1) with synchronous metastases
who have no peritoneal dissemination or other distant
metastases; and (2) with metachronous metastases, but
no other recurrent lesion. Ambiru et al. [9] added a
third criterion, that is, complete resection of hepatic me-
tastases with acceptable postoperative hepatic function.
In a recent report by Roh et al. [29], hepatic resection is
said to be indicated only in patients with hepaticmetastases in one lobe of the liver without peritoneal
dissemination, hilar node metastases, or distant metasta-
ses. Criteria actually accepted for resection of hepatic
metastases from gastric cancer are now as follows: (1)
good control of the primary tumor and complete resec-
tion of primary tumor and lymph nodes involvement in
synchronous disease; (2) no signs at preoperative work-
up of disseminated diseases, hilar lymph nodes metasta-
ses, peritoneal dissemination, or extrahepatic metastases;
(3) complete resection of hepatic metastases (macro-
scopically no residual tumor). Following these selection
criteria Ochiai et al. [30] found a hepatic resection inci-
dence of 21 in 6,540 patients (0.3%) with a gastric cancer
who underwent a gastrectomy. Saiura et al. [31] found
an incidence of 10 in 1,807 similar patients (0.6%), and
Okano et al. [27] found an incidence of 19 in 807
patients (2.4%). A recent literature review reported only
229 liver resections for LMGC, maybe reflecting an a
priori passive attitude toward these patients. Some stud-
ies report a classification of degree of liver metastases in
patients with LMGC according to the Japanese Classifi-
cation of Gastric Carcinoma (Table 1) [32]. Studies in
which synchronous en bloc resections of gastric cancer
directly invading the liver were performed were not
included in this review. In each study regarding patients
with metachronous liver metastases the resection of the
primary gastric cancer was categorized as curative or the
studies were excluded from our analysis. Curative resec-
tion was defined by removal of all macroscopically de-
tectable disease and microscopically clear resection
margins (R0). Synchronous liver metastases were defined
by detection before or during surgery in each study, or
within 3 months after primary tumor resection. The fol-
lowing clinicopathologic factors were analyzed in the lit-
erature revision to underline their influence on patient’s
outcome: age; gender; status of serosal invasion; histo-
logic differentiation of the primary tumor; status of
lymph nodes metastases; temporal relationship of metas-
tases with primary disease (synchronous or metachro-
nous); tumor distribution; size and number of liver
metastases; classification of hepatic metastases according
the Japanese Gastric Cancer Association proposal
(Table 1), type of hepatic resection; surgical margin and
completeness of the resection; presence of pseudocap-
sule between metastases and liver parenchyma,
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factors were then divided into three main categories.
1. Predictive of outcome related to primary tumor
2. Predictive of outcome related to metastases
3. Predictive of outcome related to surgery
Liver surgical procedures were classified as anatomic
resection (segmentectomy and lobectomy) or limited re-
section (all resections less extensive than segmentect-
omy). Moreover we analyzed literature regarding
prognostic factors according to two main categories of
papers: papers with selected or unselected populations.Prognostic factors
In the review of the literature hepatectomy was indicated
in only 0.4% to 1% of gastric cancer patients with liver me-
tastases. Unfortunately, most hepatic metastases from gas-
tric adenocarcinoma are multiple, bilateral, and combined
with peritoneal or lymph nodes metastases, which directly
invade adjacent organs precluding a radical surgical ap-
proach. At specialized treatment centers, the proportion
of surgery for hepatic metastases of gastric cancer is 7% to
12% of hepatic resection for all types of hepatic malignan-
cies [33]. The resectability rate is low and is approximately
10% of cases, and it seems to be the same in cases of
metachronous or synchronous metastases [34].
The effectiveness of hepatic resection has not been
well-defined. In addition, the clinicopathologic charac-
teristics related to the prognosis of gastric cancer with
hepatic metastases have not been comprehensively iden-
tified. Nevertheless the presence of hepatic metastases is
a statistically significant poor prognostic factor for
patients with gastric cancer [35]. The cumulative sur-
vival rate reported in early studies was generally poor,
reflecting a generalized disease. Elias et al. showed that
the 3-year survival after hepatic resection was less than
20% [36]. In recent series the 1-year survival rate ranged
from 42% to 90% and 5-year survival rate from 0% to
38% (Table 2). The long-term results after liver resection
for metastases from gastric cancer show a wide range
(Table 2). Most studies concerning this issue come from
Japan and the reported long-term survival rates exceed
30% in some series [24,27]. In contrast, in the western
study from Zacherl et al. none of the patients survived 5
years after resection [32].
Thus, the clinical benefit of resection of hepatic me-
tastases from gastric carcinoma is still not widely
accepted. However, non-surgical treatments, including
systemic or hepatic artery infusion chemotherapy, do
not achieve satisfactory results. In patients treated by
gastrectomy and chemotherapy, median survival times
are reported to range from 2.9 to 11.8 months [37,38].Furthermore Bines et al. [39] reported one long-term
survivor of seven (14.3%) and other series showed 11.1%
to 19% long-term survivors. Although few, the long-
term survivors after hepatic resection do exist. Therefore
to determine the indication of liver surgery is crucial
and to clarify the condition of 5-year survivors.
The actual selection criteria, accepted by many authors
(Table 2) are: (1) synchronous metastases without peri-
toneal dissemination or other distant metastases; (2)
metachronous metastases without other recurrent lesion;
and (3) complete resection of metastases with acceptable
postoperative liver function. Contraindications to hepatic
resection are: previous extrahepatic disease, advanced
lymphnode involvement, and the inability to obtain liver
R0 resection (8,23). Although Roh et al. [28] limited the
indication to one lobar distribution of metastases in a re-
cent study, it seems that the improved patient’s survival
is not observed with this limitation.
An attempt to define criteria for selection of patients
with favorable outcome has been previously made in
various series. We herein report a comprehensive review
of the literature experience of smaller and selected
population series. We classified the characteristics pre-
dictive of good or poor outcome according to the pri-
mary tumor, the metastases and the type of surgery.
Table 3 resumes the association of survival with different
prognostic factors.Predictive of outcome related to primary tumor
Regarding the primary gastric cancer Ochiai [29] reported
that hepatic resection should only be attempted in patients
with synchronous or metachronous metastases if there is
non-serosal invasion by the primary gastric tumor, as well
as the study of Morise [40] and if the primary tumor has
neither microscopic venous not lymphatic invasion in case
of metachronous cases. Furthermore Shirabe showed that
lymphatic and venous invasion of cancer cells from primary
gastric cancer are clinicopathological prognostic factors of
poor outcome at both univariate and multivariate analysis
[41]. Imamura [12] add to these parameters, the grade of
differentiation of primary tumor as a negative predictor of
outcome. Zacherl et al. [32] reported that tumor
localization of primary gastric cancer (proximal third versus
distal two-thirds of the stomach) was a marginal predictive
negative factor for overall survival of patients, while in the
study of Tsujimoto the gastric cancer size >of 6 cm was
considered a predictor of poor survival [42].
However, some studies showed these were not sig-
nificant prognostic factors and are still controversial.
Miyazaki [43] and Okano [27] reported that there was a
non-significant difference in terms of depth of invasion or
lymph node metastases of the gastric cancer between sur-
viving and non-surviving patients. Koga [33] reported a
Table 2 Literature analysis regarding hepatectomy for liver metastases from gastric cancer















1994 [30] 21 No extrahepatic
No carcinosis R0
Na 13/8 Na 14 7 0 19 19% (4)
1997 [43] 21 No extrahepatic
No carcinosis R0
Na 11/10 5/16 7 14 11/3 Na 45 19 11 24% (5) 76.1% n
2001 [23]
17 1990-1997 No extrahepatic
No carcinosis
R0 Na 7/10 na 6/11 8 9 4/5 18% 47 22 0 0 76% Na
2001 [9]
40 1975-1999 No extrahepatic
No carcinosis
R0 Na 18/22 19/21 21/19 19 21
5/16 0 70 28 18 15% (6) 75% 88
2001 [45]
10 1979-1999 Na Na 3/7 3/7 6/4 6 4
2/2 Na 60 20 20 10% (1) 80% 10-240
2002 [33]
15 1980-1999 No extrahepatic
No carcinosis
R0 Na 10/5 9/6 3/12 8 7
2/5 33 35.7 14.3 0 0 90% Na
2002 [31]
10 1981-1998 No extrahepatic
≤ 3 segments 15.6% 7/3 Na 6/4 5 5
4/1 40% 65 38 20 20% (2) 80% 1-68
2002 [28]
19 1986-1999 No extrahepatic
No carcinosis
R0 17% 13/6 na 7/12 10 9
2/7 0 77 34 34 14% (3) 74% Na
2003 [25]





















Table 2 Literature analysis regarding hepatectomy for liver metastases from gastric cancer (Continued)
R0 8% 12/10 10/12 3/19 16 6
1/5 0 73 38 38 20% (5) 68% Na
2003 [41]
36 1979-2001 Na Na 16/20 17/19 10/16 Na Na 0 64, 43, 26 11% (4) 83.3% Na
2005 [29]
11 1988-1996 No extrahepatic
No carcinosis
Solitary nodules
R0 Na 8/3 Na 2/9 11 0 0 73, 42, 27 18% (2) 80 Na
2007 [34]
42 1985-2005 No extrahepatic
No carcinosis
R0 17% 20/22 Na 7/35 29 13 0 76, 48, 42 20% (8) 67% 1-86
2007 [44]
37 1990-2005 No extrahepatic
R0
No carcinosis 12% 16/21 10/27 5/32 21 16
9/7 14% 60 27 11 6% (2) 81% Na
2008 [24]
24 1988-2002 No carcinosis
R0 Na 15/9 Na 8/16 13 11
5/6 25% 38, 16, 10 8% (2) 65% 1-67
2008 [40]
18 1989-2004 No extrahepatic
R0
Hepatic function Na 11/7 8/10 4/14 14 14 Na 56.3, 36.5, 27 17% (3) Na 2-200
2008 [37]
22 1995-2005 No extrahepatic
No carcinosis
R0
Hepatic function 7.5% 18/4 7/15 3/19 18 4
3/1 Na 77 30.4 23 15% (3) 63.6% 1-106
2009 [47]




















Table 2 Literature analysis regarding hepatectomy for liver metastases from gastric cancer (Continued)
No carcinosis
≤ 5 lesions





metachronous 15.1% 0/11 Na 1/10 8 3 0 81, 30, 20 18.2% (2) 63% 4-86
2009 [47] 72
(12)* 1991-2005 16.6% 12/0 Na 4/8 9 3 1 57, 43, 43 20% (3) Na Na
Choi 2010
14 1986-2007 No extrahepatic
No carcinosis
R0 Na 0/14 Na 4/10 9 5
2/3 0 67 38..3 8% (1) 63% Na
Tsujmoto 2010
17 1980-2007 No extrahepatic
No carcinosis
Unilobar
R0 Na 9/8 Na 6/11 13 4 Na 31 30% (5) 70% Na
Our data
2012 21 1998-2007 No extrahepatic
No carcinosis
R0 31% 12/9 10/11 4/17 12 9
4/5 10% 68 31 19 14.2% (3) 66% 6-90
H1, Metastases limited to one lobe; H2, few scattered metastases in both liver lobes; H3, numerous scattered metastases in both lobes; M, Metachronous; mets, metastases; Na, not available; S, Synchronous;
STG, Subtotal gastrectomy; TG, Total gastrectomy.




















Table 3 Analysis of prognostic factors associated with survival in patients resected for LMGC
Author year n Period T N G H DIAM metastases TIMING MARGIN MST Long-term survivors Recurrence Follow-up (months)
1994 [30] 21 + + - - NA NA NA 18 19% (4) NA
1997 [43] 21 - - - + NA - NA NA 24% (5) 76.1% NA
2001 [23] 17 1990-1997 - + + - NA + + 16 0 76% Na
2001 [9] 40 1975-1999 - - - - - + - 12 15% (6) 75% 88
2001 [45] 10 1979-1999 - - - - + + NA 16 10% (1) 80% 10-240
2002 [33] 15 1980-1999 - - - + - + - 8.8 0 90% na
2002 [31] 10 1981-1998 - - - - - - NA 25 20% (2) 80% 1-68
2002 [28] 19 1986-1999 - - + + - + NA 21 14% (3) 74% Na
2003 [25] 22 1985-2001 * - - + + - NA 24 20% (5) 68% Na
2003 [41] 36 1979-2001 - Ly - + - - - NA 11% (4) 83.3% NA
2005 [29] 11 1988-1996 NA - - NA - - - 19 18% (2) 80 Na
2007 [34] 42 1985-2005 + - - + - - - 34 20% (8) 67% 1-86
2007 [44] 37 1990-2005 + - - + + - - 31 6 % (2) 81 % Na
2008 [24] 24 1988-2002 - - - - - - + 19 8% (2) 65% 1-67
2008 [40] 18 1989-2004 + - - - - - - NA 17% (3) Na 2-200
2008 [37] 22 1995-2005 15% (3) 63.6% 1-106
2009 [47] 17 1991-2005 - - - - - - + 18 25% (4) 70.5% 1-117
Choi 2010 14 1986-2007 - - - - - - - NA 8% (1) 63% Na
Tsujmoto 2010 17 1980-2007 + Ly NA - - - NA 34 30% (5) 70% Na
Our data
2012 21 1998-2007 14.2% (3) 66% 6-90
H1, Metastases limited to one lobe; H2, few scattered metastases in both liver lobes; H3, numerous scattered metastases in both lobes; M, Metachronous; mets,
metastases; Na, Not available; S, Synchronous; STG, Subtotal gastrectomy; TG, Total gastrectomy; ● Number of patients resected on a total of patients with LMGC.
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mary tumor.
Predictive of outcome related to metastases
Number of nodules and lobar distribution
The number of the metastatic nodules in the liver has
been reported to be an important prognostic factor in
six studies. Okano et al. [27] reported 3-year survival
rates of 56% for single metastases and 0% for multiple
metastases, and the number of liver metastases was a
significant prognostic factor in other reports as well
(Table 1). In Koga et al. and Shirabe et al. [33,40] none
of the patients with multiple gastric liver metastases
(three or more lesions) survived beyond 3 years, whereas
the 5-year survival rate for patients with solitary liver
metastases was 55% with eight long-term survivors. Shir-
abe et al. [40] described the presence of three or more
tumors as an independent poor prognostic factor
according to both univariate and multivariate analysis;
moreover, all four patients who survived beyond 5 years
in their study also had solitary tumors, and almost all
patients described as long-term survivors (Table 1) had a
solitary liver metastasis. These data were confirmed in
the study of Sakamoto [24] with a survival of 56% for
solitary lesions against no long-term survivors in cases
of multiple tumors. In a more recent study Sakamoto[44] showed against the value of solitary lesion adding
unilobar distribution as a good predictive factor for sur-
vival of patients, as previously reported in the Miyazaki’s
paper [42].
In some studies the number of liver metastases was a
marginal prognostic factor for survival after hepatic sur-
gery with curative intent. The favorable survival out-
come for patients with a solitary metastasis, which was
no worse than that for a solitary metastasis of colorectal
cancer, indicates that patients with a solitary metastasis
of gastric cancer are good candidates for surgical resec-
tion . On the other hand, the surgical indications should
be considered more carefully in patients with multiple
metastases of gastric cancer than patients with multiple
metastases of colorectal cancer. Otherwise Saiura [30]
showed two long-term survivors with more than three
metastases concluding that if curative resection (R0) can
be achieved, hepatic resection should not be abandoned
even in patients with multiple liver metastases.
As for the lobar distribution of liver metastases,
patients with bilobar tumors had a worse outcome than
patients with a unilobar tumor, as shown by Zacherl et
al. [32]. However, the number and lobar distribution of
the tumors were correlated, and so the significance of
the lobar distribution of tumors as a prognostic factor
should be revaluated in larger series.
Table 4 Prognostic factors from series considering unselected populations and related survivals
















H; P; R0 resection
2009 [51] 73 Metachronous Overall: 7
BST: 5
Chemotherapy: 12





T; N; G of primary
R0 resection
2009 [52] 73 Synchronous Stage of primary; H
Extrahepatic disease;
treatment of mets
2010 [49] Synchronous +metachronous Overall: 16
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Lymphocytes aggregation, enclosing the metastatic
tumor, is reported as a good prognostic factor by Fujii
[45]. This could be explained with the favorable action
of umor infiltrating lymphocytes (TILs) in preventing
tumor extension in gastric cancer patients [46]. Okano
[27] demonstrate that the presence of a fibrous pseudo-
capsule around liver metastases is a promising indicator
of a better prognosis, being closely associated with pa-
tient survival. Pseudocapsule formation should be con-
sidered as a protective immunoinflammatory reaction
against the metastastic nodule reflecting the host
defence reaction creating a wall which stops tumor
diffusion.
Predictive of outcome related to surgery
Surgical margin >/10 mm in hepatic resection was a
good prognostic factor in some papers (Table 2).
Miyazaki [42] demonstrated significant differences in
the number of hepatic metastases (solitary of multiple)
and the size of the tumor-free resection margin (<10 mm
or >10 mm) for long- and short-term survivors. Thelen
[24] reported that a positive resection margin should be
considered a powerful determinant of poor outcome.Nomura [47] showed that the recurrence rate in the
remnant liver was higher in patients with a surgical
margin <5 mm.
The consensus seems to be that there is not apparent
value to surgery if residual disease remains, whether it is
involvement of resection margins, other distant metasta-
ses, or peritoneal carcinosis.
The relationship between the extent of hepatic resec-
tion and prognosis has not yet been established. Isono
[48] reported that micrometastases around the macro-
scopic tumor were found more frequently in hepatic me-
tastases from gastric cancer than in those from
colorectal ones, thus suggesting that wider surgical re-
section margins are required.
A positive resection margin is also not an independent
prognostic factor in colorectal liver metastases because of
its strong relationship with the number of tumors
resected. In approximately 70% of patients, recurrent dis-
ease developed after hepatic resection, most commonly in
the liver. Recurrent tumors were more frequently distribu-
ted in both lobes than in the resected lobe, suggesting that
liver recurrence is more probably derived from multiple
metastatic foci from the primary disease than from intra-
hepatic remetastases of the liver lesion
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hepatic micrometastases around the liver as a cause of re-
currence of the disease. The survival rate of patients with
micrometastases was significantly worse than that of
patients without. In addition, recurrence after hepatic re-
section is more strongly associated with systemic spread
through vessel infiltration than with local spread through
lymphatic or serosal invasion of the primary tumor. A
generous surgical margin may not be essential for curative
hepatic resection of liver metastases, even if in the study
by Ambiru [9] a margin <10 mm is considered a poor
prognostic factor for survival. Nevertheless a positive sur-
gical margin should be avoided and the surgeon should
strive to obtain an adequate margin, because this is the
only prognostic factor on which the surgeon could have
any influence over. According to the pattern of recurrence,
relapse developed most commonly in the liver (70%, range
63.6% to 83.3%), indicating that the remaining liver should
be a focus for relapse monitoring. Early or high recurrence
rates translate into prolonged periods of systemic therapy
and potentially reduced quality of life: these will mitigate
any short-term advantage resulting from liver resection in
LMGC. Data about recurrence made liver resection less
appealing. However, the majority of patients analyzed did
not receive adjuvant chemotherapy after liver resection.
Given the biology and systemic nature of LMGC, this may
partially account for the high recurrence rates. A sensible
strategy for improving survival could be close observation
for a second relapse in the liver and adjuvant chemothera-
pies after surgery. Trials using the FOLFOXIRI regimen
(5-fluorouracil, leucovorin, oxaliplatin, and irinotecan)
[20] achieved a median overall survival of 15 months. We
can assume that the recurrence rates could potentially de-
crease with these regimen in an adjuvant setting.
Timing of hepatic resection
Timing of hepatic resection has been reported to be a
significant prognostic factor. In some paper synchronous
hepatectomy was a significant poor prognostic factor.
Ambiru [9] reported significantly longer survival in
patients with metachronous metastases than in those
with synchrounous disease (29% vs. 6% at 3 years). Bines
[38] commented that synchronous resection of hepatic
metastases has little value, whereas metachronous resec-
tion of isolated lesions can produce meaningful long-
term survival, when the procedure renders the patient
disease-free. Some authors suggest that resective treat-
ment may be indicated only for the patient with meta-
chronous isolated metastases [29,42]. Other studies did
not demonstrate any differences in terms of survival
among the groups (Cheon) [36]. Nevertheless, an ana-
lysis of the data reported in the recent literature showed
that 22 of 48 5-year survivors underwent a synchronous
hepatectomy. In fact in Sakamoto’s study [43] three offive patients who survived more than 3 years had syn-
chronous solitary metastases and Ochiai too reported
three 5-year survivors with synchronous disease. Recently
Tsujimoto [41] confirm the absence of statistically differ-
ence between metachronous or synchronous nodules.
Thus, synchronous hepatectomy should not be a contra-
indication for hepatic resection. With regard to periopera-
tive morbidity, Bines [38], observed that synchronous liver
resection carries a higher risk. This may depend on the
concern regarding the use of aggressive liver surgery in
conjunction with the treatment of gastric cancer under
synchronous conditions. The disease-free interval (DFI)
between gastric and hepatic resection has been reported
to be a prognostic factor. Fujii [44] showed that a DFI > 1
year has a significant survival advantage, due to the slow
growing nature of these tumors.
However, data concerning long-term survivors demon-
strate that, if we exclude bilobar spread of metastases
(H3), none of the previous cited predictive factors (alone
or in combination) can deprive a patient of the possibil-
ity of long-term survival after hepatic resection, raising
concern about the clinical value of prognostic factors
emerging from small and selected populations submitted
to liver resection.
The correct approach can be extrapolated from papers
that addressed the topic analyzing unselected popula-
tions of gastric cancer patients presenting hepatic metas-
tases as only site of metastatic disease (Table 4). From a
cohort of 58 patients Cheon [36] did not identify any
primary-related or metastasis-related factor showing
prognostic value. The same conclusion is done by group
of Makino [49] from Japan, who studied 63 patients.
Ueda [50] studied a cohort of 73 patients presenting syn-
chronous metastases. Their data show that factors influ-
encing survival were the extent of hepatic involvement
(H1-2 vs. H3) and macroscopic peritoneal dissemination
(P0 vs. P1) detected at surgical exploration. When focus-
ing on the subgroup of H1-2 and P0 patients, they
showed that number (1 vs. >1) and size of hepatic me-
tastases and N status of gastric cancer (N0-1 vs. N2-3)
were predictors of survival. An Italian survey performed
under the auspices of the Italian Research Group on
Gastric Cancer [51] studied an unselected cohort of 73
patients presenting metachronous metastases after cura-
tive gastrectomy. This study demonstrated that the
factors T, N, and G of the gastric primary, when rated
T3b-T4, N+, and G3, independently display a clear nega-
tive prognostic value with an effect that is cumulative.
All the above mentioned studies strongly suggest that the
main factor influencing long-term survival (P ranging
from 0.01 to 0.001) is the therapeutic approach to the
liver metastases, in particular when a surgical approach
is performed. In the Italian study hepatectomy was asso-
ciated to a five-fold increase in survival of less favorable
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5-year survival rate of 20%. Comparing the treatment
options (supportive care, chemotherapy, and liver resec-
tion) they found that 1-, 3-, and 5-year survival rates
were as follows: 22%, 2%, and 0% for supportive care,
45%, 6%, and 0% after chemotherapy, and 81%, 20%, and
20% after liver resection, with a median survival as fol-
low: non-treated patients 5 months, 12 if chemotherapy
was employed and 23 months after surgery. Thus the
therapeutic approach to liver metastases displayed inde-
pendent significant association with survival. In the
study of Ueda [49] in which a group of patients with
synchronous LMGC underwent surgery or other treat-
ments (chemotherapy, supportive cures), 1-, 3-, and 5-
year overall survival rates were 57%,43%, and 43%, 60%,
0%, and 0%, and 16.7%, 0%, and 0%, respectively. Fur-
thermore in this study adding hepatic artery infusion
(HAI) chemotherapy to liver surgery not seem to offer a
survival benefit for the patients. The author suggests
that only liver surgery, but not HAI, could significantly
prolong the survival period in this cohort of patients.
Moreover the degree of liver metastases (H1-H2 vs. H3)
seems to be a very strong prognostic factor, with a me-
dian overall survival of 16.6, 10.2, and 4.4 months, re-
spectively,despite the treatment.
Furthermore, two studies [36,49] underlined that R0
vs. R1 operation affects long-term survival (overall 5-
year survival rates of 60% and 20%, respectively). Multi-
modal treatments can further enhance survival rates, in
particular if modern chemotherapy protocols are
employed. An interesting 75% 5-year survival rate in a
subgroup of eight patients submitted to radical surgery
followed by hepatic artery infusion chemotherapy has
been reported by Ueda. Radio-frequency ablation is an-
other important strategy for the treatment of hepatic
metastases from gastric cancer. This ablative technique
can be employed either as alternative or in association
to hepatectomy. It could be the approach of choice in
case of poor general conditions contraindicating surgery.
The number of reported procedures is low not allowing
to draw any conclusion on its efficacy: moreover follow-
up are short and data cannot always be effectively extra-
polated from the series. However, Hwang [52], consid-
ered 72 patients with metachronous metastases
submitted to different treatments other than hepatect-
omy (Table 4). The paper showed that 15 patients with-
out extrahepatic disease treated by RFA± chemotherapy
displayed a median survival of 22 months, with 3- and
5- year survival rates of 50% and 40%, respectively, similar
to those reported in surgical series (Table 2). Yamakado
[53] and Cheon [36] reported similar data: in their experi-
ence a subgroup of nine patients submitted to RFA com-
pared favorably with 22 patients submitted to radical
surgery, with a 4-year survival of 40% and 20%,respectively. Another paper of Kim et al. [54] report worse
survival results similar to those of classic systemic chemo-
therapy alone.
Conclusions
Some hold the view that metastatic gastric cancer repre-
sent a systemic disease and the ‘tip of the iceberg’ of a
diffuse cancer, and surgery has no role in its treatment,
because the results of liver resection are still disappoint-
ing. Otherwise 11% of patients survived more than 5
years after hepatectomy, are tumor-free more than 5
years after liver resection, and the identification of favor-
able indicators of outcome could improve these results.
The key to success is to clearly identify the patients
which could benefit of this treatment, in order to offer a
chance to cure the patients who have good prognostic
factors and to avoid overtreatment in case of absence of
these factors. Moreover analysis of long-term survival
reported in literature shows that, if we exclude cases
presenting a bilobar spread of metastases, none of the
reported predictive factors, alone or in combination, can
deprive a patient of the possibility of long-term survival
after hepatic resection. We believe that surgery could
provide a benefit and should be a part of multidisciplin-
ary approach in patients with liver metastases from gas-
tric cancer.
Compared to supportive treatment alone with a me-
dian survival of 3 to 5 months, the survival figures
reported in literature indicate that liver resection can
improve the prognosis of patients suffering from meta-
static gastric cancer, and results seems to be better than
those achieved with chemotherapy alone. Data regarding
the use of radiofrequency are interesting even if yet
under development. This is true not only in Eastern ex-
perience, but also in Western countries, and in centers
with skills and experience in liver surgery
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